ERBB2 and breast carcinoma: This resistance was highlighted by a four-fold decrease in the IC50 values for gefitinib when ATG12 gene silencing was performed in JIMT1 cells, which are HER2-resistant-positive breast cancer cells, indicative of the cytoprotective nature of gefitinib-induced autophagy [85].